Skip to content

Sino-American Tianjin SmithKline & French Laboratories

Request correction

A pharmaceutical joint venture in Tianjin, China, known as Sino-American Tianjin SmithKline & French Laboratories.

Last updated November 4, 2026

AI crawler reads

4requests

1companies
  • Anthropic4
Profile
2
Controversies
2
JSON · MD
0
First read
Nov 4, 2026
Latest read
Nov 4, 2026

From this site's server log

Overview

Sino-American Tianjin SmithKline & French Laboratories (abbreviated as Sino-American SK&F) is a pharmaceutical joint venture in the People's Republic of China, headquartered in Tianjin. Its joint venture parties are Tianjin Zhongxin Pharmaceutical Group Co., Ltd., Tianjin Pharmaceutical Group Co., Ltd., and the American company SmithKline Beecham. Its brands include Contac (compound pseudoephedrine hydrochloride sustained-release capsules), Fenbid (ibuprofen), Bactroban (mupirocin), SK&F Zental (albendazole), and Polident.

History

Sino-American Tianjin SmithKline & French Laboratories (abbreviated as Sino-American SK&F) is a pharmaceutical joint venture in the People's Republic of China, established with the United Kingdom (originally the United States at the time of founding), headquartered in Tianjin. The joint venture parties are Tianjin Zhongxin Pharmaceutical Group Co., Ltd., Tianjin Pharmaceutical Group Co., Ltd., and the American company SmithKline Beecham.

  • Sino-American Tianjin SmithKline & French Laboratories was established as a joint venture between Chinese parties (Tianjin Zhongxin Pharmaceutical Group and Tianjin Pharmaceutical Group) and the American company SmithKline Beecham.

Products and positioning

  • Contac (compound pseudoephedrine hydrochloride sustained-release capsules)

  • Fenbid (ibuprofen)

  • Bactroban (mupirocin)

  • SK&F Zental (albendazole)

  • Polident

Controversies

  • 2000

    PPA controversy: Contac suspended, losses about RMB 600 million

    In November 2000, China's drug regulator, because phenylpropanolamine (PPA) may increase the risk of hemorrhagic stroke, required suspension of use and sale of PPA-containing drugs. Sino-American SmithKline immediately stopped selling Contac and Kangde and recalled drugs from channels, with direct losses of about RMB 600 million; in 2001 it launched "New Contac" replacing PPA with PSE, and its crisis PR was regarded as a classic case. Sales suspension and recall.

Read more

Sources4 sources

Cite this profile: Cite the canonical profile. /brand-wiki/sino-american-tianjin-smithkline-and-french-laboratories · Editorial policy · How profiles are compiled